33 Result(s)

Article

Elevated CYP2C19 expression is associated with depressive symptoms and hippocampal homeostasis impairment

The polymorphic CYP2C19 enzyme metabolizes psychoactive compounds and is expressed in the adult liver and fetal brain. Previously, we demonstrated that the absence of CYP2C19 is associated with lower levels of...

M M Jukić, N Opel, J Ström, T Carrillo-Roa, S Miksys, M Novalen… in Molecular Psychiatry (2017)

Article

High frequency of CYP2D6 ultrarapid metabolizer genotypes in an Ashkenazi Jewish population from Argentina

A twofold higher frequency of CYP2D6 ultrarapid metabolizers (estimated from genotype: gUMs) was reported among Ashkenazi Jews (AJ) living in New York (USA) than in other North American Caucasians, which might be...

G Moya, P Dorado, V Ferreiro, M E G Naranjo… in The Pharmacogenomics Journal (2017)

Article

Pharmacogenetic study of antipsychotic induced acute extrapyramidal symptoms in a first episode psychosis cohort: role of dopamine, serotonin and glutamate candidate genes

This study investigated whether the risk of presenting antipsychotic (AP)-induced extrapyramidal symptoms (EPS) could be related to single-nucleotide polymorphisms (SNPs) in a naturalistic cohort of first epis...

S Mas, P Gassó, A Lafuente, M Bioque, A Lobo… in The Pharmacogenomics Journal (2016)

Article

High frequency of CYP2D6 ultrarapid metabolizers in Spain: controversy about their misclassification in worldwide population studies

A high frequency (7–10%) of CYP2D6 ultrarapid metabolizers estimated from the genotype (gUMs) has been claimed to exist among Spaniards and Southern Europeans. However, methodological aspects such as the inclu...

M E G Naranjo, F de Andrés, A Delgado, J Cobaleda… in The Pharmacogenomics Journal (2016)

Article

CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy

We aimed to explore the possible influence of CYP2C9 (*2, *3 and IVS8-109 A>T), CYP2C19 (*2, *3 and *17) and ABCB1 (1236C>T, 2677G>A/T and 3435C>T) on phenytoin (PHT) plasma concentrations in 64 Mexican Mestizo (...

A Ortega-Vázquez, P Dorado, I Fricke-Galindo, H Jung-Cook… in The Pharmacogenomics Journal (2016)

Article

Interethnic variation of CYP2C19 alleles, ‘predicted’ phenotypes and ‘measured’ metabolic phenotypes across world populations

The present study evaluates the worldwide frequency distribution of CYP2C19 alleles and CYP2C19 metabolic phenotypes (‘predicted’ from genotypes and ‘measured’ with a probe drug) among healthy volunteers from dif...

I Fricke-Galindo, C Céspedes-Garro, F Rodrigues-Soares… in The Pharmacogenomics Journal (2016)

Article

High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme

Cytochrome P450 3A4 (CYP3A4) is a key drug-metabolizing enzyme. Loss-of-function variants have been reported as rare events, and the first demonstration of a CYP3A4 protein lacking functional activity is cause...

M Apellániz-Ruiz, L Inglada-Pérez, M E G Naranjo, L Sánchez… in The Pharmacogenomics Journal (2015)

Article

Pharmacogenomic information in drug labels: European Medicines Agency perspective

Pharmacogenomics (PGx) has a growing impact on healthcare and constitutes one of the major pillars of personalised medicine. For the purpose of improved individualised drug treatment, there is an increasing ef...

F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard… in The Pharmacogenomics Journal (2015)

Article

A combined high CYP2D6-CYP2C19 metabolic capacity is associated with the severity of suicide attempt as measured by objective circumstances

This study examined, for the first time, whether a high CYP2D6-CYP2C19 metabolic capacity combination increases the likelihood of suicidal intent severity in a large study cohort. Survivors of a suicide attempt (

E Peñas-Lledó, S Guillaume, M E G Naranjo, A Delgado… in The Pharmacogenomics Journal (2015)

Article

Interethnic differences in the relevance of CYP2C9 genotype and environmental factors for diclofenac metabolism in Hispanics from Cuba and Spain

The aims of this study were to evaluate the diclofenac metabolism in Hispanics from Cuba and Spain and its relation to ethnicity, CYP2C9 genotypes and environmental factors. Diclofenac hydroxylation capacity (con...

A Llerena, M Alvarez, P Dorado, I González, E Peñas-LLedó… in The Pharmacogenomics Journal (2014)

Article

Influence of admixture components on CYP2C9*2 allele frequency in eight indigenous populations from Northwest Mexico

We previously documented the lowest frequency of CYP2C9*2 in Mexican indigenous Tepehuanos followed by Mestizos and Mexican-Americans populations, suggesting a negative correlation between the CYP2C9*2 frequency ...

M Sosa-Macías, B P Lazalde-Ramos, C Galaviz-Hernández… in The Pharmacogenomics Journal (2013)

Article

Use of pharmacogenetics in bioequivalence studies to reduce sample size: an example with mirtazapine and CYP2D6

In bioequivalence studies, intra-individual variability (CV_w) is critical in determining sample size. In particular, highly variable drugs may require enrolment of a greater number of subjects. We hypothesize tha...

N González-Vacarezza, F Abad-Santos, A Carcas-Sansuan… in The Pharmacogenomics Journal (2013)

Article

Neurological toxicity after phenytoin infusion in a pediatric patient with epilepsy: influence of CYP2C9, CYP2C19 and ABCB1 genetic polymorphisms

Pharmacogenetic studies have shown that genetic defects in drug-metabolizing enzymes encoded by CYP2C9, CYP2C19 genes and by the transporter ABCB1 gene can influence phenytoin (PTH) plasma levels and toxicity. Th...

P Dorado, E López-Torres, E M Peñas-LLedó, J Martínez-Antón… in The Pharmacogenomics Journal (2013)

Article

CYP2D6 ultrarapid metabolism and early dropout from fluoxetine or amitriptyline monotherapy treatment in major depressive patients

E M Peñas-LLedó, H D Trejo, P Dorado, A Ortega, H Jung, E Alonso… in Molecular Psychiatry (2013)

Article

CYP2D6 polymorphism in patients with eating disorders

CYP2D6 polymorphism is associated with variability in drug response, endogenous metabolism (that is, serotonin), personality, neurocognition and psychopathology. The relationship between CYP2D6 genetic polymorphi...

E M Peñas-LLedó, P Dorado, Z Agüera, M Gratacós, X Estivill… in The Pharmacogenomics Journal (2012)

Article

CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans

CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs) and 260 Cubans divided into Cuban Mestizos (CMs) and White Cubans (WCs). The frequencies of poor metabolizers (...

A LLerena, P Dorado, R Ramírez, I González, M Álvarez… in The Pharmacogenomics Journal (2012)